These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20855856)

  • 21. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
    Moore DJ
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
    Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J
    J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LRRK2 and Parkinson disease.
    Dächsel JC; Farrer MJ
    Arch Neurol; 2010 May; 67(5):542-7. PubMed ID: 20457952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in LRRK2 as a cause of Parkinson's disease.
    Giasson BI; Van Deerlin VM
    Neurosignals; 2008; 16(1):99-105. PubMed ID: 18097165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corticobasal syndrome and primary progressive aphasia as manifestations of lrrk2 gene mutations.
    Ross OA; Toft M; Haugarvoll K
    Neurology; 2008 Jul; 71(4):303; author reply 303-4. PubMed ID: 18645174
    [No Abstract]   [Full Text] [Related]  

  • 26. The importance of LRRK2 mutations in Parkinson disease.
    Schapira AH
    Arch Neurol; 2006 Sep; 63(9):1225-8. PubMed ID: 16966498
    [No Abstract]   [Full Text] [Related]  

  • 27. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LRRK2 gene variation and its contribution to Parkinson disease.
    Paisán-Ruiz C
    Hum Mutat; 2009 Aug; 30(8):1153-60. PubMed ID: 19472409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease.
    Yescas P; López M; Monroy N; Boll MC; Rodríguez-Violante M; Rodríguez U; Ochoa A; Alonso ME
    Neurosci Lett; 2010 Nov; 485(2):79-82. PubMed ID: 20727385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation.
    Deng H; Le W; Guo Y; Hunter CB; Xie W; Jankovic J
    Ann Neurol; 2005 Jun; 57(6):933-4. PubMed ID: 15929036
    [No Abstract]   [Full Text] [Related]  

  • 31. Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease.
    Toft M; Mata IF; Ross OA; Kachergus J; Hulihan MM; Haugarvoll K; Stone JT; Blazquez M; Gibson JM; Aasly JO; White LR; Lynch T; Adler CH; Gwinn-Hardy K; Farrer MJ
    Mov Disord; 2007 Feb; 22(3):389-92. PubMed ID: 17216639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease.
    Zabetian CP; Morino H; Ujike H; Yamamoto M; Oda M; Maruyama H; Izumi Y; Kaji R; Griffith A; Leis BC; Roberts JW; Yearout D; Samii A; Kawakami H
    Neurology; 2006 Aug; 67(4):697-9. PubMed ID: 16728648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lrrk2 mutations in South America: A study of Chilean Parkinson's disease.
    Perez-Pastene C; Cobb SA; Díaz-Grez F; Hulihan MM; Miranda M; Venegas P; Godoy OT; Kachergus JM; Ross OA; Layson L; Farrer MJ; Segura-Aguilar J
    Neurosci Lett; 2007 Jul; 422(3):193-7. PubMed ID: 17614198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of LRRK2 functional domains in nondominant Parkinson disease.
    Skipper L; Shen H; Chua E; Bonnard C; Kolatkar P; Tan LC; Jamora RD; Puvan K; Puong KY; Zhao Y; Pavanni R; Wong MC; Yuen Y; Farrer M; Liu JJ; Tan EK
    Neurology; 2005 Oct; 65(8):1319-21. PubMed ID: 16247070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LRRK2 mutations and Parkinsonism.
    Albrecht M
    Lancet; 2005 Apr 2-8; 365(9466):1230. PubMed ID: 15811455
    [No Abstract]   [Full Text] [Related]  

  • 36. New LRRK2 variants identified in Parkinson's disease.
    Tan EK; Schapira AH
    Eur J Neurol; 2011 Mar; 18(3):369-70. PubMed ID: 20629720
    [No Abstract]   [Full Text] [Related]  

  • 37. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP.
    Spanaki C; Latsoudis H; Plaitakis A
    Neurology; 2006 Oct; 67(8):1518-9. PubMed ID: 17060595
    [No Abstract]   [Full Text] [Related]  

  • 38. A study of LRRK2 mutations and Parkinson's disease in Brazil.
    Pimentel MM; Moura KC; Abdalla CB; Pereira JS; de Rosso AL; Nicaretta DH; Campos M; de Almeida RM; dos Santos JM; Bastos IC; Mendes MF; Maultasch H; Costa FH; Werneck AL; Santos-Rebouças CB
    Neurosci Lett; 2008 Mar; 433(1):17-21. PubMed ID: 18201824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease.
    Elbaz A
    Lancet Neurol; 2008 Jul; 7(7):562-4. PubMed ID: 18539536
    [No Abstract]   [Full Text] [Related]  

  • 40. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population.
    Funayama M; Li Y; Tomiyama H; Yoshino H; Imamichi Y; Yamamoto M; Murata M; Toda T; Mizuno Y; Hattori N
    Neuroreport; 2007 Feb; 18(3):273-5. PubMed ID: 17314670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.